Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Synklino has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Synklino's investors include BioInnovation Institute, Maj Invest Equity, EIR Ventures, Vaekstfonden, PKA.
Synklino is headquartered in Lyngby, Denmark.
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Synklino is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synklino — Funding & Investors." VCBacked, June 8, 2022, https://www.vcbacked.co/company/synklino. Accessed August 14, 2026.
VCBacked. (2022). Synklino — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/synklino
{{cite web |title=Synklino — Funding & Investors |url=https://www.vcbacked.co/company/synklino |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated